ARV Use During Pregnancy and Birth Defects
Researchers looked at birth defect rates among participants in the PACTG 316 trial. Those who initiated ARV use during the first trimester of pregnancy were no more likely to have infants with birth defects than those who initiated ARV treatment during second or third trimesters. There is a questionable association between exposure to ARV in utero and heart defects that requires further study.
Citation:
Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofeson L, Stanley K, Newell M, Mandelbro L, Delfraissy J, Cunningham CK. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011 March;39(2):163-170.
Original Article (subscription may be required)
Abstract
Citation:
Watts DH, Huang S, Culnane M, Kaiser KA, Scheuerle A, Mofeson L, Stanley K, Newell M, Mandelbro L, Delfraissy J, Cunningham CK. Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med. 2011 March;39(2):163-170.
Original Article (subscription may be required)
Abstract
